secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tourmaline Bio, Inc. (—)
CIK:        0001827506
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001827506-24-000032
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tourmaline Bio Q1 2024 net loss $13.3M; cash $350.3M; Phase 2 TRANQUILITY initiated
--------------------------------------------------------------------------------

- Net loss $13.3M ($0.55 basic/diluted loss per share) for Q1 2024, compared to $7.5M ($8.28) in Q1 2023.
- Cash, cash equivalents and investments $350.3M as of March 31, 2024, providing cash runway into 2027.
- Initiated Phase 2 TRANQUILITY trial in ASCVD/CKD in April 2024; topline data expected in H1 2025.
- Plans to initiate pivotal Phase 3 trial for TOUR006 in TED in H2 2024; Phase 2b spiriTED topline in 2025.
- Completed $172.5M follow-on offering in January 2024, net proceeds $161.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/0001827506-24-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827506/000182750624000032/trml-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001827506-24-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer